Therapeutic Response

BRAF p.V600K status confers therapeutic sensitivity to Nivolumab in patients with Melanoma.

Statements

Source and description
Opdivo (nivolumab) [product monograph]. HC. Health Canada approved nivolumab for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor.